apo-valsartan valsartan 160 mg tablets bottle
arrotex pharmaceuticals pty ltd - valsartan, quantity: 160 mg - tablet - excipient ingredients: powdered cellulose; calcium hydrogen phosphate dihydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 8000; titanium dioxide; iron oxide yellow; iron oxide red; purified water; hyprolose; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see clinical trials).
apo-valsartan valsartan 80 mg tablets bottle
arrotex pharmaceuticals pty ltd - valsartan, quantity: 80 mg - tablet - excipient ingredients: powdered cellulose; calcium hydrogen phosphate dihydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 8000; titanium dioxide; iron oxide yellow; iron oxide red; purified water; hyprolose - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see clinical trials).
apo-valsartan valsartan 40 mg tablets bottle
arrotex pharmaceuticals pty ltd - valsartan, quantity: 40 mg - tablet - excipient ingredients: calcium hydrogen phosphate dihydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hyprolose; macrogol 8000; titanium dioxide; iron oxide yellow; iron oxide red; purified water; hypromellose; powdered cellulose - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see clinical trials).
valsartan- valsartan tablet, film coated
remedyrepack inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 320 mg - valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detect
pharmacor sacubitril valsartan sacubitril/valsartan 49/51 mg film-coated tablet blister pack
pharmacor pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.
pharmacor sacubitril valsartan sacubitril/valsartan 24/26 mg film-coated tablet bottle pack
pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.
teva-valsartan tablet
teva canada limited - valsartan - tablet - 320mg - valsartan 320mg - angiotensin ii receptor antagonists
novo-valsartan tablet
teva canada limited - valsartan - tablet - 320mg - valsartan 320mg - angiotensin ii receptor antagonists
pms-valsartan tablet
pharmascience inc - valsartan - tablet - 320mg - valsartan 320mg - angiotensin ii receptor antagonists
dom-valsartan tablet
dominion pharmacal - valsartan - tablet - 320mg - valsartan 320mg - angiotensin ii receptor antagonists